[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2023004465A - Composiciones basadas en virus y métodos para redirigir respuestas inmunitarias preexistentes mediante su uso para el tratamiento del cáncer. - Google Patents

Composiciones basadas en virus y métodos para redirigir respuestas inmunitarias preexistentes mediante su uso para el tratamiento del cáncer.

Info

Publication number
MX2023004465A
MX2023004465A MX2023004465A MX2023004465A MX2023004465A MX 2023004465 A MX2023004465 A MX 2023004465A MX 2023004465 A MX2023004465 A MX 2023004465A MX 2023004465 A MX2023004465 A MX 2023004465A MX 2023004465 A MX2023004465 A MX 2023004465A
Authority
MX
Mexico
Prior art keywords
compositions
methods
inspired
virus
subject
Prior art date
Application number
MX2023004465A
Other languages
English (en)
Inventor
Joshua Weiyuan Wang
Ken Matsui
Philip Storm
Kristin Marie Peter
Original Assignee
Verimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Verimmune Inc filed Critical Verimmune Inc
Publication of MX2023004465A publication Critical patent/MX2023004465A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20051—Methods of production or purification of viral material
    • C12N2710/20052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se describen composiciones basadas en virus y métodos de preparación de estas, donde las composiciones comprenden proteínas L1 del virus del papiloma mutante que forman, de manera espontánea, estructuras principales de cápsides y que se conjugan con un péptido que comprende un epítopo para formar cápsides de redireccionamiento inmunitario (IRC). Los epítopos en los péptidos se diseñan para ser reconocidos por el sistema inmunitario de un sujeto en función de la memoria inmunitaria preexistente del sujeto desarrollada a partir de la exposición previa del sujeto al epítopo a través de infección o vacunación. Las proteínas L1 del virus del papiloma mutante poseen tres mutaciones que incluyen un truncamiento en el extremo amino, un truncamiento en el extremo carboxi, y un truncamiento en la cuarta hélice. Estas mutaciones en la proteína L1 producen capsómeros que forman estructuras principales de cápsides con geometría T=1 no canónicas. Se describen usos y métodos de uso de las composiciones para el tratamiento y/o la prevención de cánceres en sujetos que los necesitan.
MX2023004465A 2020-10-19 2021-10-19 Composiciones basadas en virus y métodos para redirigir respuestas inmunitarias preexistentes mediante su uso para el tratamiento del cáncer. MX2023004465A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063093525P 2020-10-19 2020-10-19
US202163220485P 2021-07-10 2021-07-10
PCT/US2021/055676 WO2022087013A1 (en) 2020-10-19 2021-10-19 Virus-inspired compositions and methods of redirecting preexisting immune responses using the same for treatment of cancer

Publications (1)

Publication Number Publication Date
MX2023004465A true MX2023004465A (es) 2023-06-19

Family

ID=81291907

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023004465A MX2023004465A (es) 2020-10-19 2021-10-19 Composiciones basadas en virus y métodos para redirigir respuestas inmunitarias preexistentes mediante su uso para el tratamiento del cáncer.

Country Status (9)

Country Link
US (2) US11858964B2 (es)
EP (1) EP4228687A1 (es)
JP (1) JP2023552040A (es)
KR (1) KR20230129379A (es)
AU (1) AU2021364548A1 (es)
CA (1) CA3195963A1 (es)
IL (1) IL302190A (es)
MX (1) MX2023004465A (es)
WO (1) WO2022087013A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018289540B2 (en) * 2017-06-23 2024-06-13 Verimmune Inc. Chimeric virus-like particles and uses thereof as antigen-specific redirectors of immune responses
CN116970574B (zh) * 2023-06-26 2024-02-09 广东省农业科学院动物卫生研究所 一种鹅源波形蛋白的用途、促进增殖鹅星状病毒的方法及用途、疫苗

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020164350A1 (en) 1992-09-03 2002-11-07 Lowy Douglas R. Chimeric papillomavirus-like particles
US8062642B1 (en) 1993-03-09 2011-11-22 University Of Rochester Production of papillomavirus capsid protein and virus-like particles
US20020039584A1 (en) 1998-02-20 2002-04-04 Medigene Ag Papilloma virus capsomere vaccine formulations and methods of use
KR100715954B1 (ko) 1998-12-04 2007-05-09 바이오겐 아이덱 엠에이 인코포레이티드 펩티드 리간드에 의하여 부착된 다중 면역원성 성분을보유한 ｈｂｖ 코어 항원 입자
SE514982C2 (sv) 1999-09-30 2001-05-28 Active Biotech Ab Bärare innehållande ett huvudkapsidprotein L1 från humant papillomavirus samt dess användning
US9045727B2 (en) 2002-05-17 2015-06-02 Emory University Virus-like particles, methods of preparation, and immunogenic compositions
GB2392158B (en) 2002-08-21 2005-02-16 Proimmune Ltd Chimeric MHC protein and oligomer thereof
MXPA05009580A (es) 2003-03-07 2005-10-19 Merck & Co Inc Vacuna contra el virus de la influenza.
EP1622928A4 (en) 2003-05-09 2006-06-14 Res Dev Foundation INSERTION OF FURINE PROTEASE CLEAVAGE SITES IN MEMBRANE PROTEINS AND USES THEREOF
US20070160628A1 (en) 2005-08-31 2007-07-12 Birkett Ashley J Stabilized virus-like particles and epitope display systems
US20070104689A1 (en) 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
KR20080090412A (ko) 2005-12-08 2008-10-08 유니버시티 오브 루이빌 리서치 파운데이션, 인코포레이티드 생체내 세포 표면 엔지니어링
US8778351B2 (en) 2006-08-30 2014-07-15 University Of Rochester Combined human papillomavirus VLP/gene delivery system and use thereof as a vaccine for prophylaxis and immunotherapy of infectious diseases and tumors
US8394411B2 (en) 2007-05-08 2013-03-12 The United States of America as represented by the Secretary, Dept. of Health and Human Services National Institutes of Health Papillomavirus pseudoviruses for detection and therapy of tumors
WO2009055491A2 (en) 2007-10-22 2009-04-30 University Of Rochester Respiratory syncytial virus vaccine based on chimeric papillomavirus virus-like particles or capsomeres
US20110091496A1 (en) 2008-01-19 2011-04-21 Graham Barney S Methods and compositions for the delivery of vaccines to disrupted epithelium
BRPI0915076A2 (pt) 2008-06-09 2017-03-14 Bharat Biotech Int Ltd composições de vacina, composição imunogênica, método para expressão dos antígenos quiméricos de hpv-hbsag supramencionados, composição farmacêutica, método para ocasionar resposta de anticorpo protetor para composição antigênica e/ou resposta de célula t citotóxica, uso das formulações antigênicas supramencionadas.
EP2416798B1 (en) 2009-04-10 2017-09-20 The Johns Hopkins University Papillomavirus-like particles (vlp) as broad spectrum human papillomavirus (hpv) vaccines
ES2683352T3 (es) 2009-04-13 2018-09-26 Inserm - Institut National De La Santé Et De La Recherche Médicale Partículas de HPV y usos de las mismas
BRPI1014494A2 (pt) 2009-04-30 2016-08-02 Coley Pharm Group Inc vacina pneumocócica e usos da mesma
WO2012033911A2 (en) 2010-09-08 2012-03-15 The Johns Hopkins University Polyionic papilloma virus-like particle (vlp) vaccines
WO2012123755A1 (en) 2011-03-17 2012-09-20 The University Of Birmingham Re-directed immunotherapy
WO2013019658A2 (en) 2011-07-29 2013-02-07 Selecta Biosciences, Inc. Synthetic nanocarriers comprising polymers comprising multiple immunomodulatory agents
WO2013080187A1 (en) 2011-12-01 2013-06-06 University Of Cape Town Hpv chimaeric particle
WO2013119877A1 (en) 2012-02-07 2013-08-15 Aura Biosciences, Inc. Virion-derived nanospheres for selective delivery of therapeutic and diagnostic agents to cancer cells
US20130295553A1 (en) * 2012-05-04 2013-11-07 University Of Louisville Research Foundation Compositions and methods relating to mouse papilloma virus
WO2014043523A1 (en) 2012-09-14 2014-03-20 The Johns Hopkins University Compositions and methods for rendering tumor cells susceptible to cd8+ t cell-mediated killing
JP2016515538A (ja) 2013-03-15 2016-05-30 ブレット バイオテクノロジー、 インク．Ｂｕｌｌｅｔ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ， Ｉｎｃ． 特異的な多価ウイルス様粒子ワクチンおよびその使用
DK3046583T3 (da) 2013-09-18 2019-05-20 Aura Biosciences Inc Viruslignende partikelkonjugater til behandling af tumorer
AU2015218365A1 (en) 2014-02-14 2016-09-01 Immune Design Corp. Immunotherapy of cancer through combination of local and systemic immune stimulation
WO2015196112A1 (en) 2014-06-19 2015-12-23 The Regents Of The University Of Colorado, A Body Corporate Human papilloma virus constructs
RU2746021C2 (ru) 2015-02-18 2021-04-06 Ф.Хоффманн-Ля Рош Аг Иммуноконъюгаты для специфической индукции цитотоксичности т-клеток против клеток-мишеней
JP6909728B2 (ja) 2015-04-28 2021-07-28 アルバート アインシュタイン カレッジ オブ メディシン 弱毒化細菌によって送達されるリコール抗原を使用する癌の治療
WO2017020570A1 (en) 2015-08-06 2017-02-09 Medigen Biotechnology Corp. Virus-like particle vaccines
WO2017075615A1 (en) 2015-10-29 2017-05-04 Bullet Biotechnology, Inc. Virus-like particle intermediates, agents attached thereto, methods for making and uses thereof
JP2018532801A (ja) 2015-10-30 2018-11-08 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 標的化がん療法
US11129882B2 (en) 2015-10-30 2021-09-28 University Of Copenhagen Virus like particle with efficient epitope display
US20180311374A1 (en) 2015-10-30 2018-11-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Targeted cancer therapy
US10722537B2 (en) 2015-11-06 2020-07-28 Regents Of The University Of Minnesota Activation of resident memory T cells for cancer immunotherapy
CA3003482A1 (en) 2015-11-19 2017-05-26 Revitope Limited Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells
WO2017112830A1 (en) 2015-12-21 2017-06-29 La Jolla Institute For Allergy And Immunology Leveraging immune memory from common childhood vaccines to fight disease
WO2017112797A1 (en) 2015-12-22 2017-06-29 Thomas Jefferson University Intra-lesional cmv-based cancer vaccines
WO2017177204A1 (en) 2016-04-09 2017-10-12 La Jolla Institute For Allergy And Immunology Leveraging immune memory from common childhood vaccines to fight disease
US20200078401A1 (en) 2016-12-07 2020-03-12 La Jolla Institute For Allergy And Immunology Compositions for cancer treatment and methods and uses for cancer treatment and prognosis
US11197890B2 (en) 2016-12-12 2021-12-14 New York Society For The Relief Of The Ruptured And Crippled, Maintaining The Hospital For Special Surgery Methods of treating cancer, infectious disease, and autoimmune disease using CXC chemokines
AU2018289540B2 (en) * 2017-06-23 2024-06-13 Verimmune Inc. Chimeric virus-like particles and uses thereof as antigen-specific redirectors of immune responses
EP3661550A4 (en) 2017-08-03 2021-08-04 Regents of the University of Minnesota ACTIVATION OF LYMPHOCYTES T MEMORY RESIDENTS FOR THE TREATMENT OF CANCER
KR20200084883A (ko) 2017-11-06 2020-07-13 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 기존의 미생물 면역을 활용한 암 치료
WO2020017962A1 (en) 2018-07-16 2020-01-23 Dcprime B.V. A combination product for use in tumor vaccination.
AU2019414934A1 (en) * 2018-12-27 2021-06-24 Verimmune Llc Conjugated virus-like particles and uses thereof as anti-tumor immune redirectors
CN113905718A (zh) 2019-03-26 2022-01-07 奥拉生物科学公司 人乳头瘤病毒纳米粒制剂

Also Published As

Publication number Publication date
WO2022087013A1 (en) 2022-04-28
KR20230129379A (ko) 2023-09-08
US11858964B2 (en) 2024-01-02
US20240294577A1 (en) 2024-09-05
IL302190A (en) 2023-06-01
CA3195963A1 (en) 2022-04-28
US20220135624A1 (en) 2022-05-05
EP4228687A1 (en) 2023-08-23
JP2023552040A (ja) 2023-12-14
AU2021364548A1 (en) 2023-06-08

Similar Documents

Publication Publication Date Title
CN107434827B (zh) 用作诱导抗原特异性t细胞反应的免疫原性增强剂的融合蛋白
MX2023004465A (es) Composiciones basadas en virus y métodos para redirigir respuestas inmunitarias preexistentes mediante su uso para el tratamiento del cáncer.
Kumar et al. HPV vaccine: Current status and future directions
Gomez-Gutierrez et al. Vaccination with an adenoviral vector expressing calreticulin-human papillomavirus 16 E7 fusion protein eradicates E7 expressing established tumors in mice
HUP0303173A2 (hu) Csökkent immunogenitású, módosított anti-EGFR-ellenanyagok
RU2003101965A (ru) Лечение инфекции, вызываемой вирусом папилломы человека
Campo et al. A peptide encoding a B-cell epitope from the N-terminus of the capsid protein L2 of bovine papillomavirus-4 prevents disease
WO2006014579A3 (en) Enhancing class i antigen presentation with synthetic sequences
TR199801722T2 (xx) Peptit imm�nojenler.
MXPA02005639A (es) Induccion de respuestas celulares iinmunologicas al virus de papiloma humano y utilizacion de composiciones de peptidos y acidos nucleico.
DE69533295D1 (de) Melanoma-assoziierte Antigene, Epitope davon und Impstoffe gegen Melanoma
ME00183B (me) Novi postupak za deregulaciju amiloida
CN108743937B (zh) 疫苗组合物和方法
Monroy-García et al. Immunization with an HPV-16 L1-based chimeric virus-like particle containing HPV-16 E6 and E7 epitopes elicits long-lasting prophylactic and therapeutic efficacy in an HPV-16 tumor mice model
ZA202210992B (en) Antigen specific immunotherapy for covid-19 fusion proteins and methods of use
WO2002070006A8 (en) Long peptides of 22-45 amino acid residues that induce and/or enhance antigen specific immune responses
Nakagawa et al. Cross-reactivity, epitope spreading, and de novo immune stimulation are possible mechanisms of cross-protection of nonvaccine human papillomavirus (HPV) types in recipients of HPV therapeutic vaccines
HK1093314A1 (en) Recombinant adenylate cyclase toxin of bordetella induces t cell responses against tumoral antigens
WO2023024609A1 (zh) 一种新型冠状病毒疫苗的佐剂及其应用和新型冠状病毒二价重组疫苗
CN114409744B (zh) Hpv抗原表位及其鉴定方法、应用
CN111295200A (zh) 作为疫苗中的佐剂的包含合成的神经节苷脂gm3变体的纳米颗粒
ATE360642T1 (de) Mhc klasse i peptidepitope des humanen tumorassoziierten antigens 5t4
JP2003510064A (ja) ワクチン
ZA200101295B (en) Vaccine comprising cytokine-induced heat shock proteins (HSP).
ID18726A (id) Melanoma yang disesuaikan analog-analog peptida vaksin-vaksin yang melawan melanoma